Apogee Therapeutics, Inc. (APGE) Downgraded to Neutral by Guggenheim

Market Context

Apogee Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $132.69 with a market capitalization of $3.8B. The stock has gained 216.7% over the past 52 weeks.

Analyst downgrades can weigh on a stock in the short term as institutional investors who follow Guggenheim's research adjust their positions. However, downgrades also sometimes create buying opportunities if the market overreacts to the rating change. The reasoning behind the downgrade matters more than the rating itself.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Apogee Therapeutics, Inc.

Among the 10 most recent ratings: 0 Buy, 10 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 24, 2026	Stifel	Hold	N/A
Jun 24, 2026	TD Cowen	Hold	N/A
Jun 24, 2026	Guggenheim	Neutral	N/A
Jun 24, 2026	Mizuho	Neutral	N/A
Jun 23, 2026	Citigroup	Neutral	N/A

Related Tools: Analyst Ratings Dashboard | View APGE Stock Page